TASMI Tablets are indicated for the treatment of essential hypertension. It may be used alone or in combination with other antihypertensive agents.
Telmisartan 40mg + Hydrochlorothiazide 12.5mg
DOSAGE AND ADMINISTRATION
Dosage of TASMI (Telmisartan) Tablets must be individualized; the usual starting dose of TASMI (Telmisartan) Tablets is 40mg once a day. Blood pressure response is dose related over the range of 20-80mg. TASMI (Telmisartan) Tablets may be taken with or without food.
The usual effective dose of TASMI (Telmisartan) Tablets is 40mg once daily. Some patients may already benefit at a daily dose of 20mg. In cases where the target blood pressure is not achieved, telmisartan dose can be increased to a maximum of 80mg once daily. When considering raising the dose, it must be borne in mind that the maximum antihypertensive effect is generally attained four-eight weeks after the start of treatment.
Renal impaired patients
No dose adjustment is required in patients with mild to moderate renal impairment. Limited experience is available in patients with severe renal impairment or hemodialysis. A lower starting dose of 20mg is recommended in these patients.
Hepatic impaired patients
In patients with mild to moderate hepatic impairment the dosage should not exceed 40mg once daily.
Adverse effects reported from telmisartan have generally been mild and transient in nature and have only infrequently required discontinuation of therapy. The incidence of adverse events were not dose related.
Common: Symptoms of infection (e.g., urinary tract infections including cystitis), upper respiratory tract infections including pharyngitis and sinusitis, abdominal pain, diarrhea, dyspepsia, eczema, arthralgia, back pain (e.g., sciatica), muscle spasms or pain in extremity, myalgia, chest pain and influenza-like illness.
Uncommon: Anxiety, visual disturbance, vertigo, dry mouth, flatulence, hyperhidrosis and tendonitis.
Rare: Stomach discomfort.